LOGIN  |  REGISTER
Amneal Pharmaceuticals

HCA Healthcare to Present at March Healthcare Conferences

February 20, 2025 | Last Trade: US$481.06 2.92 0.61

NASHVILLE, Tenn. / Feb 20, 2025 / Business Wire / HCA Healthcare, Inc. (NYSE: HCA), is scheduled to present virtually at the following healthcare conferences:

March 4, 2025 at 1:50pm ET at TD Cowen’s 45th Annual Healthcare Conference.

March 11, 2025 at 1:30pm ET at Barclays’ 27th Annual Global Healthcare Conference.

March 19, 2025 at 2:15pm ET at KeyBanc’s 5th Annual Healthcare Forum.

March 20, 2025 at 10:00am ET at Oppenheimer’s 35th Annual Healthcare MedTech & Services Conference.

A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.

Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.

About HCA Healthcare

Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 190 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom.

All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

Astria Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page